Page 112 - Clinical Program In Primary Sclerosing Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical program in primary sclerosing cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Program In Primary Sclerosing Cholangitis Today - Breaking & Trending Today

Welcome To IANS Live - INTERNATIONAL - Possible new combo therapy for head and neck cancer

According to the researchers, head and neck cancer is the sixth most common cancer worldwide, and while effective treatments exist, sadly, cancer often returns. ....

New York , United States , India Private , News Service , All Rights , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , இந்தியா ப்ரைவேட் , செய்தி சேவை , அனைத்தும் உரிமைகள் ,

Welcome To IANS Live - SCIENCE - Possible new combo therapy for head and neck cancer

According to the researchers, head and neck cancer is the sixth most common cancer worldwide, and while effective treatments exist, sadly, cancer often returns. ....

New York , United States , India Private , News Service , All Rights , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , இந்தியா ப்ரைவேட் , செய்தி சேவை , அனைத்தும் உரிமைகள் ,

Welcome To IANS Live - TopStory - Covid-19 vaccine development process to be showcased in Republic Day parade

Indi ....

New Delhi , India Private , News Service , Republic Day , All Rights , புதியது டெல்ஹி , இந்தியா ப்ரைவேட் , செய்தி சேவை , குடியரசு நாள் , அனைத்தும் உரிமைகள் , தடுப்பு மருந்துகள் ,

Welcome To IANS Live - NATION - 13,000 volunteers given 2nd dose of Covaxin: Bharat Biotech

Suchitra Ella, Joint Managing Director, Bharat Biotech International Limited, thanked the volunteers for their pro-vaccine public health volunteerism.The ....

Andhra Pradesh , India Private , News Service , Bharat Biotech , All Rights , ஆந்திரா பிரதேஷ் , இந்தியா ப்ரைவேட் , செய்தி சேவை , பாரத் பயோடெக் , அனைத்தும் உரிமைகள் ,

Genkyotex Announces Update for Near Term Clinical Development Plan for Setanaxib

Genkyotex Announces Update for Near Term Clinical Development Plan for Setanaxib
(Paris:GKTX) (Brussels:GKTX)
(Euronext Paris Brussels: FR0013399474 GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced clinical and governance updates.
Clinical update
Following the positive results from the Phase 1 study announced in January of 2021, which evaluated higher doses of setanaxib in healthy subjects, Genkyotex is planning to initiate a pivotal Phase 2/3 study in primary biliary cholangitis (PBC), starting in the 2
nd half of 2021, with final design and protocol details subject to feedback from the US Food and Drug Administration (FDA).
In addition, the Company plans to initiate this year a Phase 2 proof-of-concept study in patients with head and neck cancer. The trial will evaluate administration of setanaxib, targeting cancer associated fibroblasts (CAFs), in conjunction with immunotherapy. ....

United States , Bruxelles Capitale , Elias Papatheodorou , Philippe Wiesel , Alexandre Grassin , Victor Thannickal , United States National Institutes Of Health , Serum Institute , Drug Administration , University Of Alabama At Birmingham , Regulatory News , Euronext Paris Brussels , Executive Vice President , Chief Medical Officer , Calliditas Therapeutics , Euronext Paris , Euronext Brussels , Kidney Disease , United States National Institutes , Professor Victor Thannickal , India Private Ltd , ஒன்றுபட்டது மாநிலங்களில் , ப்ரூக்ஸெல்ஸ் தலைநகரம் , ஒன்றுபட்டது மாநிலங்களில் தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , சீரம் நிறுவனம் , பல்கலைக்கழகம் ஆஃப் அலபாமா இல் பர்மிங்காம் ,